Lexicon Pharmaceuticals Inc

This proposal asks shareholders to approve an amendment to the company’s certificate of incorporation to increase authorized common shares from 450 million to 900 million. Management frames this as a pro forma housekeeping and strategic flexibility measure: with a larger authorized share pool the company can more readily issue equity for acquisitions, financings, or to settle equity awards without the time and expense of seeking immediate shareholder approvals. The filing notes that a preferred-holder affiliate of Invus would automatically convert into common shares upon approval (subject to conditions) and that certain equity plan awards and outstanding warrants factor into pro forma counts; this conversion would increase Invus’s potential ownership to the majority range, which is material governance context for investors. The board states it has no present plans to issue the additional shares other than the contemplated conversions and plan settlements, but the expanded authorization could nonetheless be used opportunistically, which can raise dilution concerns for existing holders. The company emphasizes that preemptive rights for holders of 20% or more remain in place and would not change, but that does not mitigate dilution for smaller shareholders. From a governance perspective, the amendment transfers power to the board to issue additional capital (subject to minority protections and any required approvals) and thus investors should weigh both the operational flexibility and the dilution/ownership-concentration consequences. Vote recommendation: the board recommends “FOR” because it believes the additional authorization will facilitate strategic transactions and plan-sourced issuances; sophisticated investors will assess this against the company’s near-term capital needs, governance safeguards, and the potential increase in Invus’s converted stake.

This management proposal requests shareholder approval to amend and restate the company’s existing equity plan principally to extend its term and increase the authorized share pool from 75 million to 90 million shares. Management frames the change as necessary to preserve the company’s ability to grant long-term equity awards (options, RSUs, SARs and performance awards) used to attract, retain and incentivize employees, directors and consultants; the filing also states the board approved the amendment on February 12, 2026, subject to shareholder approval. Key governance considerations include the size of the requested additional share reserve (a 20% increase) relative to the outstanding share count and current overhang, the potential for dilution from future awards, and the plan mechanics (e.g., full reload of forfeited shares, net-exercise rules, and the committee’s discretionary grant authority). The filing discloses current outstanding options and RSUs, and notes certain awards are conditioned on shareholder approval of the Seventh Amended and Restated Certificate of Incorporation because settlement in shares depends on the increased authorized shares—this linkage elevates the materiality of the certificate amendment. Compensation-alignment rationale: management emphasizes alignment of employee pay with stockholder returns and benchmarking to peer groups, while retaining discretion on grant sizes and recipients. Risk controls disclosed include an aggregate plan limit, committee administration (compensation committee), transfer and repricing constraints, and the company’s clawback policy; however, investors will weigh whether these controls sufficiently constrain dilution and opportunistic timing. The board recommends a "FOR" vote; investors should consider potential dilution against the expected benefit of retaining talent and executing the company’s development and commercialization plans.

Management requests shareholder approval to amend and restate the directors’ equity plan, primarily to extend its term and expand the share reserve from 4 million to 6 million shares to preserve future grant capacity for non-employee directors. The company states these awards (nonstatutory options, RSUs and restricted stock) are intended to align directors’ long-term interests with those of stockholders and notes a per-director annual grant-value cap of $500,000 (including cash fees) intended to limit extreme dilution per director. Governance considerations include the incremental dilution relative to the outstanding share base and the company’s overall equity overhang; however, the annual per-director cap is a meaningful constraint compared to unconstrained grant policies. The plan continues committee (board) administration and contains repricing/substitution and change-in-control provisions; it also contemplates that restricted stock units currently payable in cash would be settleable in shares upon approval of the Seventh Amended and Restated Certificate of Incorporation, linking this plan’s practical effect to Proposal 2. From a stewardship perspective, investors should weigh the benefits of director retention and alignment against dilution, and review historical director grant levels and overall governance safeguards. The board recommends a "FOR" vote; institutional investors will evaluate whether the proposed reserve and guardrails are consistent with best practices and the company’s capital needs.

This is a routine, non-binding "say-on-pay" advisory vote asking shareholders to approve the company’s disclosed executive compensation. Management’s supporting case emphasizes that its compensation program is designed to attract and retain talent and align pay with long-term shareholder value, and notes the committee will consider the outcome in future decisions. Key analytical points: the proxy provides detailed CD&A, benchmarking peer groups, a clawback policy, and historical pay-versus-performance disclosure; investors should evaluate how pay outcomes map to company performance, the mix of cash vs. equity, the size and timing of grants, and any one-time payments or severance provisions (including recently adopted management severance plan). Because the vote is advisory, a negative result would not automatically change pay but would signal shareholder discontent and likely prompt engagement and potential adjustments by the compensation committee. Given the company received strong support on say-on-pay in the prior year (over 96% in favor), the committee interprets that as validation of its approach but will continue to monitor feedback. The board recommends a "FOR" vote; institutional investors will assess the alignment between realized pay and demonstrated performance, governance safeguards (clawback, committee independence) and the potential dilution from recent equity grants.